Law plays an important role in the pharmaceutical industry and concerns compliance with laws and regulations such as GMP, GCP and GDP as well as the protection of intellectual property, especially patents. Contract law is also relevant as pharmaceutical companies often enter into contracts with other companies. Overall, the law sets out the framework conditions for the development, manufacture and marketing of medicinal products and protects companies' investments and business objectives.
Pharmaceutical companies must comply with numerous regulatory requirements to ensure that their medicines are safe and effective. The most important requirements include Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Distribution Practice (GDP), approval procedures, pharmacovigilance and advertising regulations. The approval process varies by country and region, but generally requires data from clinical trials to demonstrate the safety and efficacy of the drug. Pharmaceutical companies must also have a system for monitoring the safety of medicines and ensure that their advertising complies with applicable regulations.
The approval process for new drugs involves several steps, which can vary depending on the region and regulatory authority. The steps of the approval process in the European Union and the United States include a preliminary phase in which preclinical studies are conducted, followed by Phase I, II and III clinical trials. Upon completion of Phase III, a marketing authorization application is submitted to the relevant regulatory authority, which is reviewed to assess the efficacy, safety and quality of the drug. If the drug is deemed safe and effective, the regulatory authority grants marketing authorization.
